Smart Glasses Deployment Kit

Vuzix Corp (VUZI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release Vuzix Reports Second Quarter 2026 Results ROCHESTER, N.Y., August 13, 2026 - Vuzix ® Corporation (NASDAQ: VUZI ), (“Vuzix” or, the “Company”), a leading supplier of AI-powered smart glasses, waveguides and Augmented Reality (AR) technologies, today repo

Vuzix (NASDAQ: VUZI) reported Q2 2026 results for the three months ended June 30, 2026. Total revenue fell 14% to $1.1 million from $1.3 million. Gross loss narrowed to $0.6 million. Net loss attributable to common shareholders was $7.7 million, or $0.09 per share. Cash was $17.3 million with no debt.

Vuzix reported Q1 2026 revenue of $1.4M, down 12% YoY, citing weaker sales of its M400 enterprise smart glasses. The CFO said the decline reflects product maturity and that Vuzix is shifting toward an OEM and waveguide-focused model, expecting near-term revenue erosion. Engineering services rose 36% to $350K. EPS was a $0.09 loss. CEO said Ultralight Pro OEM smart glasses will begin shipping to Amazon in Q2 2026.

Pharmaceutical companies like Samsung Bioepis, Formycon, Zydus, Celltrion, and Amgen are racing to develop biosimilars for MSD's top-selling cancer drug Keytruda, as its patent nears expiration. Samsung Bioepis filed for FDA approval, while Formycon and Zydus are already under review. MSD is defending its market with a new subcutaneous formulation, Keytruda Qlex, and plans to acquire new drugs.

Intel announced its Nova Lake desktop processor, built on the enhanced 18A-P process, will launch in 2026 and is ahead of schedule. The chip offers up to 9% more speed or 18% lower power compared to 18A. Intel is repurposing Panther Lake wafer capacity for Granite Rapids server chips, indicating a focus on data center and AI demand. Q3 2026 revenue was $16.5B, up 21% YoY, with Client Computing revenue down 5% YoY. Intel expects a PC market slowdown through mid-2027, citing memory price impacts.

Anteris Technologies reported 30-day results from the EMBARK Study for its DurAVR heart valve, showing low pressure gradients, large valve openings, and no valve-related deaths. The study involved 22 patients with severe aortic stenosis. The company is also conducting the PARADIGM trial, a global study comparing DurAVR to existing valves.